Similar articles

• The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.

  Rosato RR, Almenara JA, Coe S, Grant S. Rosato RR, et al. Cancer Res. 2007 Oct 1;67(19):9490-500. doi: 10.1158/0008-5472.CAN-07-0598. Cancer Res. 2007. PMID: 17909059
• Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.

  Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S. Dasmahapatra G, et al. Clin Cancer Res. 2007 Jul 15;13(14):4280-90. doi: 10.1158/1078-0432.CCR-07-0835. Clin Cancer Res. 2007. Retraction in: Clin Cancer Res. 2016 Oct 1;22(19):4959. doi: 10.1158/1078-0432.CCR-16-1914. PMID: 17634558 Retracted.
• The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.

  Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, Santacana M, Gonzalez-Tallada FJ, Matias-Guiu X, Dolcet X. Llobet D, et al. Eur J Cancer. 2010 Mar;46(4):836-50. doi: 10.1016/j.ejca.2009.12.025. Epub 2010 Jan 12. Eur J Cancer. 2010. PMID: 20071162
• Mcl-1: a gateway to TRAIL sensitization.

  Kim SH, Ricci MS, El-Deiry WS. Kim SH, et al. Cancer Res. 2008 Apr 1;68(7):2062-4. doi: 10.1158/0008-5472.CAN-07-6278. Cancer Res. 2008. PMID: 18381408 Review.
• Clearing the TRAIL for Cancer Therapy.

  Hall MA, Cleveland JL. Hall MA, et al. Cancer Cell. 2007 Jul;12(1):4-6. doi: 10.1016/j.ccr.2007.06.011. Cancer Cell. 2007. PMID: 17613431 Review.